Clinical Trial Update: Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating romiplostim for persistent thrombocytopenia in patients who have received an allogeneic hematopoietic stem cell transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | Phase 1, Phase 2 | Status: COMPLETED